Revance Therapeutics reported $13.27M in Trade Creditors for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Trade Creditors Change
Aerie Pharmaceuticals AERI:US $ 9.28M 1.4M
ALKERMES ALKS:US 40.05M 12.35M
Bristol Myers Squibb BMY:US $ 2882M 62M
Cara Therapeutics CARA:US $ 9.74M 4.15M
Coherus Biosciences CHRS:US $ 17.49M 3.61M
Eli Lilly And LLY:US $ 1659.3M 226M
Endo International Ordinary Shares ENDP:US $ 90.64M 10.36M
Horizon Pharma HZNP:US $ 18.54M 48.48M
JAZZ PHA JAZZ:US $ 74.16M 0.82M
Pacira Pharmaceuticals PCRX:US $ 13.98M 0.86M
Procter & Gamble PG:US $ 14882M 707M
Revance Therapeutics RVNC:US $ 13.27M 3.25M
Teva Pharmaceutical Industries TEVA:US $ 1901M 151M